Anti-Mucin1 aptamer-conjugated chitosan nanoparticles for targeted co-delivery of docetaxel and IGF-1R siRNA to SKBR3 metastatic breast cancer cells

Background: Targeted co-delivery of siRNA and a chemotherapeutic drug is an attractive approach to cancer drug design and treatment. This study was carried out to design an anti-Mucin1 aptamer [Apt]-conjugated chitosan nanoparticle [NP] for targeted co-delivery of insulin-like growth factor receptor 1 [IGF-1R] Silencer siRNA and docetaxel [DTX] to SKBR3 cells

Methods: Characterization of nano-drugs, cellular uptake of NPs, cell viability, and gene expression studies were evaluated based on metastatic breast cancer cells

Results:The results of this study showed that NPs had spherical and smooth morphology with 110-118 nm in size and had positive zeta potential [12-14 mV]. siRNA and DTX were considerably loaded into NPs. The appropriate conjugation of the Apt to the NPs was affirmed by gel electrophoresis. The Apt-conjugated NPs were observed to enhance the cellular uptake of NPs into the SKBR3 cells. Although the combination treatment significantly decreased the cell viability of SKBR3 cells, the augmentative effect was observed when Apt was conjugated to NPs. Furthermore, Apt-conjugated NPs dramatically reduced the genetic expression of IGF-1R, signal transducers and activators of transcription 3 [STAT3], matrix metalloproteinases [MMP9], and vascular growth factor [VEGF]

Conclusion: The targeted NPs may augment the targeting of pathways involved in tumorigenesis and metastasis of breast cancer. Therefore, more animal model experiments are needed to further clarify the efficacy and safety of this functionalized nanodrug

Generation and characterization of anti-CD34 monoclonal antibodies that react with hematopoietic stem cells

CD34 is a type I membrane protein with a molecular mass of approximately 110 kDa. This antigen is associated with human hematopoietic progenitor cells and is a differentiation stage-specific leukocyte antigen. In this study we have generated and characterized monoclonal antibodies [mAbs] directed against a CD34 marker. Mice were immunized with two keyhole lympet hemocyanin [KLH]-conjugated CD34 peptides. Fused cells were grown in hypoxanthine, aminopterine and thymidine [HAT] selective medium and cloned by the limiting dilution [L.D] method. Several monoclones were isolated by three rounds of limited dilutions. From these, we chose stable clones that presented sustained antibody production for subsequent characterization. Antibodies were tested for their reactivity and specificity to recognize the CD34 peptides and further screened by enzyme-linked immunosorbent assay [ELISA] and Western blotting analyses. One of the mAbs [3D5] was strongly reactive against the CD34 peptide and with native CD34 from human umbilical cord blood cells [UCB] in ELISA and Western blotting analyses. The results have shown that this antibody is highly specific and functional in biomedical applications such as ELISA and Western blot assays. This monoclonal antibodies [mAb] can be a useful tool for isolation and purification of human hematopoietic stem cells [HSCs]

Increased IL-17A but decreased IL-27 serum levels in patients with multiple sclerosis

Effector CD4[+] T cell subsets play an important role in Multiple Sclerosis [MS]. Interleukin-27 [IL-27] suppresses Th [Th1, Th2 and Th17] cells and dampens autoimmunity and tissue inflammation by promoting the generation of Type 1 regulatory T cells [Tr1]. To identify the relative levels of IL-27 and IL-17A in MS disease. In a case-control study, venous blood was collected from forty MS patients and forty-three healthy subjects as control group. Serum levels of IL-27 and IL- 17A were measured by ELISA method. A significant difference between serum IL-17A concentration in patients [120.68 +/- 209.85 pg/ml] and control group [67.26 +/- 117.76 pg/ml, p=0.016] was found. Serum IL-27 levels of the MS patients [159.7 +/- 581.4 pg/ml] were significantly lower than control subjects [180.35 +/- 507.84 pg/ml, p=0.001]. Our findings show decreased levels of IL-27 against increasing IL-17A levels in patients group which may suggest the suppressive role of IL-27 on inflammatory process of MS